1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Panchsheel Organics Limited

Panchsheel Organics Limited

PANCHSHEEL.BO
Panchsheel Organics LimitedIN flagBombay Stock Exchange
122.00
INR
-0.75
- -
1.61BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
33.3
39.06
35.69
40.27
37.76
40.8
48.08
50.23
97.72
68.8
93.27
79.87
81.3
78.37
Basic EPS, GAAP
1.26
1.75
1.89
3.03
3.2
3.66
4.02
5.27
9.98
8.33
12.78
10.71
10.47
9.14
Free Cash Flow per Basic Share
-0.71
2.24
-0.12
-0.28
-0.71
2.27
1.48
4.07
6.19
-3.27
-3.55
-0.25
-8.9
- -
Dividend per Share
- -
0.04
0.29
0.6
0.45
0.4
0.47
0.49
1.28
0.66
3.21
2.68
3
- -
Book Value per Share
14.22
15.5
16.44
19.68
22.07
24.99
28.3
32.9
74.13
44.77
51.66
51.73
58.44
- -
Tangible Book Value per Share
15.98
17.45
18.45
21.18
23.77
26.89
30.4
35.2
79.13
47.26
87.26
94.93
101.63
- -
Basic Weighted Avg Shares
10
10
10
10
10
10
10
10
5
10
11
13
13
13
Sales/Revenue/Turnover
334
392
358
404
379
409
482
504
490
690
1,027
1,052
1,071
1,032
Operating Margin (%)
7.12
8.61
13.86
11.16
14.43
14.32
12.35
15.7
16.05
16.81
17.8
16.37
14.38
11.89
Depreciation Expense
10
11
15
13
12
12
12
11
11
12
16
17
22
23
Net Income, GAAP
13
18
19
30
32
37
40
53
50
84
141
141
138
120
Effective Tax Rate (%)
28.16
34.77
31.28
27.23
36.01
29.17
28.65
27.65
31.37
26.67
26.22
27.24
23.77
19.62
Profit Margin (%)
3.79
4.49
5.3
7.53
8.48
8.98
8.37
10.5
10.21
12.11
13.7
13.41
12.88
11.66
Working Capital
103
118
148
150
154
177
210
250
271
383
525
733
645
- -
LT Debt
5
6
21
15
10
6
1
- -
10
10
5
3
2
- -
Total Equity
160
175
185
212
238
270
305
353
397
474
961
1,250
1,339
- -
Return on Invested Capital (%)
7.88
9.87
14.3
12.57
11.69
12.5
12.19
14.93
12.76
17.58
17.38
10.72
8.67
- -
Return on Capital (%)
6.31
10.75
10.59
14.2
12.92
13.35
13.1
15.29
13.17
18.67
25.48
20.7
17.66
85.02
Return on Common Equity (%)
8.92
11.8
11.85
16.78
15.33
15.57
15.11
17.23
14.27
20.37
27.65
22.57
19.01
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
37
- -
LT Borrowings
- -
2
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
13
- -
Market Capitalization
1,992
1,784
1,711

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
908
- -
Cash, Cash Equivalents & STI
- -
38
- -
Accounts Receivable, Net
- -
377
- -
Inventories
- -
468
- -
Total Current Liabilities
- -
274
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
37
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.07%
34.34%
7.06%
Free Cash Flow
322.78%
642.95%
3,516.6%
Net Income, GAAP
24.9%
25.6%
-2.22%
Sales/Revenue/Turnover
12.81%
18.22%
1.8%
Total Cash Common Dividend
56.83%
95.33%
12.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
246
237
256
313
1,052
2025
261
272
262
276
1,071
2026
236
253
267
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.89
3.02
3.15
- -
10.71
2025
2.6
2.88
2.79
- -
10.47
2026
2.16
1.98
2.79
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.68
2025
- -
- -
- -
- -
3
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Mahendra Abhaychand Turakhia
Full Time Employees
178
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
137, 138, Hubtown Solaris Mumbai India
IPO Date
Jun 13, 2006
Website
panchsheelorganics.com
Similar Companies
BIMI International Medical Inc. (BIMI)
Hisamitsu Pharmaceutical Co., Inc. (HTSUY)
Medivir AB (publ) (0GP7.L)
Alibaba Health Information Technology Limited (ALBBY)
Sunil Healthcare Limited (SUNLOC.BO)
PCI Biotech Holding ASA (0JGL.L)
Business
Panchsheel Organics Limited, founded in 1989 and headquartered in Mumbai with manufacturing facilities in Indore, Madhya Pradesh, manufactures and exports active pharmaceutical ingredients, intermediates, finished formulations for human and veterinary use; nutraceuticals; vitamins, hormones, and steroids; agri biotech products including biofertilizers, biostimulants, and growth promoters; aquaculture products; dehydrated culture media; probiotics and enzymes; micro pellets, direct compression granules, and sustained/modified release pellets; as well as specialty chemicals such as insecticides, herbicides, pesticides, fungicides, viricides, water-soluble fertilizers, and plant growth regulators. The company operates primarily from India with exports to international markets and offers custom synthesis, contract manufacturing, and job work for APIs, drug intermediates, and formulations; its product portfolio spans categories like cardiovascular, neuropsychiatry, antifungal, fluoroquinolones, antiallergic, anti-inflammatory, gastrointestinal, oncology, over-the-counter remedies, and animal health supplements. In recent developments, Panchsheel Organics allotted equity shares on a preferential basis in September 2022 to fund Phase 1 capex of Rs 40 crore at Pithampur and Indore for probiotics and enzymes production with 36-40 TPA capacity targeting Rs 40-50 crore revenue by FY25; it is advancing Phase 2 capex of Rs 50-70 crore at DMIC Vikram Udyogpuri Biotech Park for fermentation-based and API pharmaceuticals adding 36-40 TPA fermentation and 120 TPA API capacity; the board declared an interim dividend for the quarter ended June 30, 2025 in August 2025 and continues reporting steady financial results including unaudited quarterly outcomes through September 2025.